Skip to main content

Benjamin Reed, James Fullerton-Batten, Nick Ash, Matt Pomroy

Epistem has completed its board appointments: Benjamin Reed will join as commercial director — he had previously served as Epistem's pharmacogenomics business development director; James Fullerton-Batten joins the board from Concept Life Sciences, where he served as finance director; Nick Ash joins the board from Source BioScience, where he served as CEO; and Matt Pomroy joins the board as a non-executive investor representative from Foresight Group.


The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.